The company has lost over 63% of its market value in the past six months, but Jefferies analyst Roger Song cited encouraging ...

Nektar (NKTR) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Nektar Therapeutics (NKTR) stock climbed as Jefferies upgraded the company to buy ahead of a Phase 2b trial readout for ...

Fintel reports that on April 11, 2025, Jefferies upgraded their outlook for Nektar Therapeutics (NasdaqCM:NKTR) from Hold to ...